Whole-body PET with 18F-FDG has proven to be a very effective imaging modality for
staging of malignant tumors. This study was performed to evaluate the impact of 18F-FDG …

The rationale was to develop recommendations on the use of 18F-FDG PET in breast,
colorectal, esophageal, head and neck, lung, pancreatic, and thyroid cancer; lymphoma …

Computed tomography (CT) and magnetic resonance imaging (MRI) have had an immense
impact on the practice of oncology. These techniques give information about structural or …

Positron emission tomography (PET) using 2-18 F-fluoro-2-deoxy-D-glucose (FDG), a
radioactive derivative of glucose, is an advanced imaging tool, based on the increased …

Since the introduction of 18F-FDG in 1976 (1)(Figs. 1–2), the last 3 decades have witnessed
a revolution in medical imaging. The widespread use of 18F-FDG PET as a molecular probe …

18F-FDG PET is a molecular whole-body imaging modality that is increasingly being used
for diagnosing, staging, and restaging cancer. The objective of this study was to determine …

This study assessed the clinical performance of a combined PET/CT system using 18F-FDG
in oncologic patients. Methods: 18F-FDG PET/CT was used to evaluate 204 patients with …

Fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging is increasingly used
for the management of patients with cancer. The technique is now well accepted by most …

The aim of this study was to evaluate the usefulness of 18 F-FDG PET in the diagnosis and
staging of primary and recurrent malignant head and neck tumours in comparison with …

Background [18F] FDG imaging on total-body PET/CT (TB PET/CT) scanners, with improved
sensitivity, offers new potentials for cancer diagnosis, staging, and radiation treatment …